Botulinum toxin type A for the treatment of the upper limb spasticity after stroke: a meta-analysis

Arquivos de Neuro-Psiquiatria

Eduardo Cardoso¹  Bernardo Rodrigues¹  Rita Lucena¹  Irismar Reis De Oliveira¹  Glícia Pedreira¹  Ailton Melo¹ 

[1] ,Federal University of Bahia Division of Neurology and Epidemiology Salvador BA ,Brazil

关键词: stroke;    spasticity;    botulinum toxin;    rehabilitation;    AVC;    espasticidade;    toxina botulínica;    reabilitação;   

DOI  :  10.1590/S0004-282X2005000100006

来源: SciELO

【 摘 要 】

Muscle over-activity is one of the cardinal features of spasticity and it is a common disability of stroke patients. In this group, spasticity is responsible for several limitations that interfere in their daily activities and quality of life. To treat spasticity, neurologists usually prescribe drugs as baclofen, tizanidine or benzodiazepines or even use definitive treatment as phenol or surgery. Authors suggest the use of botulinum toxin type A (BTX-A) for spasticity in the upper limbs after stroke, but there are few papers with adequate methodology supporting this idea. In this article we summarize the data of previous double-blind, randomised clinical trials to asses, with a meta-analysis, if BTX-A is an adequate treatment for spasticity due to stroke. The results show a statistical superiority of BTX-A ov%r placebo on reducing muscle tone by the Modified Ashworth Scale (WMD= 0.95 [0.74 to 1.17]) in patients with post-stroke upper limb spasticity.

【 授权许可】

CC BY   
 All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License